 "Apax Partners acquires subsidiaries of Spanish pharma firm Invent Farma")
Don't want to miss the best from Business Standard?
Funds advised by Apax Partners announced on July 8, 2016 that an entity controlled by them has entered into a definitive agreement to acquire the operating subsidiaries of Invent Farma SL, a leading Spanish pharmaceutical company, from a consortium of investors led by Silfurberg, Framtakssjoour Islands (Enterprise Investment Fund) and Horn II.
Located in Barcelona, Invent Farma develops, manufactures and markets generic drugs. It owns and operates manufacturing plants in Spain and comprises three divisions – Inke (an active pharmaceutical ingredients maker), Lesvi (a manufacturer of finished dosage forms) and Qualigen (which markets generic drugs in Spain).
Steven Dyson, partner and co-head of healthcare at Apax Partners, said, “We have identified the European generics space as an attractive investment area. We are excited to build on Invent Farma’s success, particularly on their strength in respiratory APIs and their outstanding CNS franchise. We will look to support the organic growth of Invent Farma as well as further consolidate the European generics market, as evidenced by our recent announcement of a transaction with Germany’s Neuraxpharm.”
Invent Farma deal follows Apax Partners acquisition of Neuraxpharm Arzneimittel GmbH, a leading German pharmaceutical company, from Atax GmbH and Neuraxpharm Holding. Located in Langenfeld near Dusseldorf, Neuraxpharm is a leader in generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS).
